Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products

Thicha Satapitanon/iStock via Getty Images Allogene Therapeutics, Inc. (NASDAQ:ALLO) has been able to advance a few CAR-T products in its pipeline. The reason why I believe that it is good to focus on this biotech next is because it is gearing up to report results from two early-stage studies, which could possibly boost shareholder value. The first candidate of which is known as cema-cel [formerly ALLO-501A] that is being advanced for the treatment of patients with relapsed/refractory chronic lymphocyti ...